UK launch update
Wegovy pill launched in the UK, what is live now and what follows on 20 July
The Wegovy pill launched for UK patients on 6 July 2026 after MHRA approval on 11 June 2026. The first live strengths are 1.5mg and 4mg, with 9mg and 25mg due to follow on 20 July. Private prescription is the practical route covered by this launch update; NHS access is a separate question governed by the relevant NHS and NICE pathway.
Published: 14 June 2026 | Last checked: 12 July 2026 | Category: Updates
Immediate answer
The launch is live now, but supply is phased
- 1.5mg and 4mg are available now through private provider routes.
- 9mg and 25mg are scheduled to follow from 20 July 2026.
- Private prescription is the realistic route for the foreseeable future.
- NHS access is a separate pathway and should be checked against current NHS and NICE guidance.
- GLP-1 medicines remain prescription-only and require a clinical assessment.
Launch-day pricing is now visible across multiple UK providers, but the higher strengths are still rolling into stock. That means a live starter-dose price does not always tell you what the maintenance dose will cost later in July.
What changed on 6 July 2026
This is no longer just an approval story. It is now a live UK launch story with a phased dose rollout, provider-specific pricing and a clear split between private access and later NHS questions.
Launch day reality
Providers can now take consultations and show live starter-dose pricing for the Wegovy pill in the UK.
Phased strengths
1.5mg and 4mg are the opening strengths; 9mg and 25mg follow from 20 July rather than all appearing on day one.
Private-only access
Commercial access is private and prescription-only. NHS use remains a separate, slower process.
Price interpretation
Starter-dose prices can be much lower than the 25mg maintenance dose, so compare the full ladder rather than a single headline figure.
Approval vs launch vs NHS access
MHRA approval on 11 June 2026 made the medicine lawful for the UK market. The 6 July 2026 launch is the commercial step, where providers can begin taking consultations and publishing prices. NHS access is a different question and should be checked against current NHS and NICE guidance rather than inferred from private provider availability.
That distinction matters because readers often see one headline and assume all three steps happened at once. They did not. The cleanest reading today is: approved, launched privately, NHS still years away.
Commercial availability
What “available now” really means
Available now means a provider is taking real consultations and has published a live route for the Wegovy pill. It does not mean every strength is in stock today, and it does not mean every visible page has the same dispatch timeline.
- Check the exact strength that is live today.
- Check whether the provider shows a real public price.
- Check whether higher strengths are dated for later in July.
- Keep starter-dose and maintenance-dose pricing separate.
NHS access vs private access
NHS access
NHS use will depend on the slower NICE and commissioning pathway. Nothing in today’s launch suggests a near-term NHS route.
Private access
Private providers are the real launch route now. They can move faster on consultations, live pricing and phased stock updates.
For users comparing routes today, private access is the practical question. NHS access is a longer-horizon policy question and should not be confused with the current launch.
Rybelsus vs Wegovy pill
Rybelsus remains the established oral semaglutide name in UK diabetes care, but it is not the same thing as the new Wegovy pill launch for weight management. Today’s change is that oral semaglutide now has a dedicated UK weight-management route under the Wegovy name.
That makes the Wegovy pill its own commercial and prescribing story, even though both medicines sit inside the wider oral semaglutide conversation.
| Topic | Rybelsus | Wegovy pill |
|---|---|---|
| UK role | Established oral semaglutide in diabetes care | New oral semaglutide route for weight management |
| Current availability | Already established in regulated care | Launched privately on 6 July 2026 with phased strengths |
| What not to assume | Do not assume weight-loss licensing | Do not assume NHS access or full-stock availability |
Wegovy pill provider monitoring
Tablet Compare now tracks which providers are live now, which still show only a future route, and which are waiting on later strengths. That is more useful on launch day than a generic “being monitored” label because the market is now split between live starter doses and later maintenance-dose rollout.
What to watch
Look for the exact live strength, the dispatch wording and whether the provider publishes a full dose ladder or only a starter price.
What not to assume
Do not treat every “available now” claim as proof that 9mg and 25mg are already shipping; many providers are launching those later in July.
What to check next
Start with the live UK compare table, then check whether the provider has published only the 1.5mg and 4mg starter strengths or the full ladder through 25mg. That is the fastest way to avoid mistaking a launch-day starter offer for a full long-term price.
Private access is now real, but it is still provider-specific. NHS access remains separate and should not shape a launch-day buying decision.
Related pages
Current UK GLP-1 Tablet Status
Use the tracker for today’s live route, phased strengths and provider movement.
GLP-1 Tablets UK
Use the hub for the broader oral weight-loss tablet picture and future pipeline context.
Compare providers
Use the provider comparison page when you want live pricing and route-by-route checks.
Wegovy pill UK
Use the product page for the cleanest launch-day route summary.
Rybelsus weight loss UK
Use the Rybelsus page for the separate oral semaglutide context in UK diabetes care.
Sources & Methodology
Use the methodology page when you want the evidence rules behind our live availability checks.
Source note
Primary regulatory source
First GLP-1 tablet for weight loss approved in the UK remains the core regulatory reference. Tablet Compare then checks live provider pages to separate approval from real commercial access and phased stock availability.
Keep launch-day pricing in context
The Wegovy pill is now live privately in the UK. Compare the starter dose, check the 20 July strength rollout, and keep NHS expectations separate from today’s private market.
Final safety note
Information only
Tablet Compare is information only. GLP-1 medicines are prescription-only medicines and clinical assessment is required. Avoid unregulated sellers, social media sellers or any route claiming tablet access without proper checks.